ArticleFrontiers in microbiology2021
Silver Nanoparticles Functionalized With Antimicrobial Polypeptides: Benefits and Possible Pitfalls of a Novel Anti-infective Tool.
Article in Frontiers in microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 50 citations in OpenAlex.
- Multivalent Display of Antimicrobial Peptides on Plant Virus Scaffolds Enhances Killing of Drug-Resistant Bacteria.ACS nano · 2026Article
- Synergistic antimicrobial nanocomposite: Protamine-loaded PVP-capped silver nanoparticles for combating multidrug-resistant infections.Asian journal of pharmaceutical sciences · 2026Article
- Antimicrobial Peptide Papiliocin-Carbon Nanotube Hybrids: Potential Dual-Action Agents for Antimicrobial Activity and Apoptotic Cancer Cell Death.Molecules (Basel, Switzerland) · 2026Article
- Temporin-GHa-derived peptides enhance the antibacterial and antibiofilm activities of polymyxin B against Pseudomonas aeruginosa and Escherichia coli.Archives of microbiology · 2026Article
- Biomolecular strategy for designing antibiotic-silver nanoparticles conjugate via nitrate reductase mediated β-lactamase inhibition with molecular docking insights.Scientific reports · 2026Article
- Emerging strategies of bacterial adaptation mechanisms to silver and metal oxide nanomaterials.FEMS microbiology reviews · 2026Review
- Nanosystems for delivery of indolicidin peptide.Frontiers in medical technology · 2026Review
- Nanosystems Containing Proteins: From Fundamentals to Applications.Chemistry, an Asian journal · 2026Review
- Synergistic effect of A novel antimicrobial peptide and silver nanoparticles against drug-resistant P. aeruginosa.AMB Express · 2025Article
- Smart hybrid nanomaterials for chronic infections: microbiome-responsive and sustainable therapeutic platforms.Journal of nanobiotechnology · 2025Review
- Current Status of the Application of Antimicrobial Peptides and Their Conjugated Derivatives.Molecules (Basel, Switzerland) · 2025Review
- Protein-based nanoparticles for antimicrobial and cancer therapy: implications for public health.RSC advances · 2025Review
- Silver Nanoparticles: A Versatile Tool Against Infectious and Non-Infectious Diseases.Antibiotics (Basel, Switzerland) · 2025Review
- Article
- Sustainable, scalable nanotechnology approach using filtrate fromFrontiers in cellular and infection microbiology · 2025Article
- Polymeric nanocarrier-based adjuvants to enhance a locally produced mucosal coryza vaccine in chicken.Scientific reports · 2024Article
- Effect of Peptides on the Synthesis, Properties and Wound Healing Capacity of Silver Nanoparticles.Pharmaceutics · 2023Article
- Nanosilver: An Old Antibacterial Agent with Great Promise in the Fight against Antibiotic Resistance.Antibiotics (Basel, Switzerland) · 2023Review
- Comparison of the Antibacterial Effect of Silver Nanoparticles and a Multifunctional Antimicrobial Peptide on Titanium Surface.International journal of molecular sciences · 2023Article
- Fungal-Mediated Silver Nanoparticle and Biochar Synergy against Colorectal Cancer Cells and Pathogenic Bacteria.Antibiotics (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Silver nanoparticles (AgNPs) and antimicrobial peptides or proteins (AMPs/APs) are both considered as promising platforms for the development of novel therapeutic agents effective against the growing number of drug-resistant pathogens. The observed synergy of their antibacterial activity suggested the prospect of introducing antimicrobial peptides or small antimicrobial proteins into the gelatinized coating of AgNPs. Conjugates with protegrin-1, indolicidin, protamine, histones, and lysozyme were comparatively tested for their antibacterial properties and compared with unconjugated nanoparticles and antimicrobial polypeptides alone. Their toxic effects were similarly tested against both normal eukaryotic cells (human erythrocytes, peripheral blood mononuclear cells, neutrophils, and dermal fibroblasts) and tumor cells (human erythromyeloid leukemia K562 and human histiocytic lymphoma U937 cell lines). The AMPs/APs retained their ability to enhance the antibacterial activity of AgNPs against both Gram-positive and Gram-negative bacteria, including drug-resistant strains, when conjugated to the AgNP surface. The small, membranolytic protegrin-1 was the most efficient, suggesting that a short, rigid structure is not a limiting factor despite the constraints imposed by binding to the nanoparticle. Some of the conjugated AMPs/APs clearly affected the ability of nanoparticle to permeabilize the outer membrane of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.